Egle Therapeutics

Egle-Therapeutics

Egle is advancing best-in-class IL-2 muteins and a proprietary Treg-targeting platform to treat cancer and autoimmune disorders. By selectively starving immunosuppressive Tregs, Egle aims to unlock durable responses in oncology and diseases such as atopic dermatitis, hidradenitis suppurativa, and type 1 diabetes.

Location: Paris, France
Board observer: Dirk Reyn
Website:
egle-tx.com

Related news

2025-06-10
Egle Therapeutics to Present New Preclinical Data EGL-003, a Novel IL-2 Mutein for Selective Expansion of Tregs to Restore Immune Balance with Best-in-class Potential, at EULAR 2025 Congress
2025-05-30
Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001 at 2025 ASCO Annual Meeting
2025-04-14
Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting
2025-01-28
Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030
2025-01-13
Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer
2024-05-09
EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member
2024-04-04
Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting
2021-08-16
Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers